We are live on ! Find out more
TECP

Trails Edge Capital Partners Portfolio holdings

AUM $630M
This Fund
S&P 500
This Quarter Est. Return
+16.76%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$630M
AUM Growth
+$193M
Cap. Flow
+$111M
Cap. Flow %
17.7%
Top 10 Hldgs %
50.32%
Holding
40
New
13
Increased
10
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
TRAX
First Tracks Biotherapeutics
TRAX
+$28.3M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$28M
3
INSM icon
Insmed
INSM
+$27.9M
4
KLRA
Kailera Therapeutics
KLRA
+$21.6M
5
INCY icon
Incyte
INCY
+$15.4M

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$38.5M
2
DFTX
Definium Therapeutics
DFTX
+$32.9M
3
RCUS icon
Arcus Biosciences
RCUS
+$22.6M
4
RVMD icon
Revolution Medicines
RVMD
+$18.9M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.15%
2 Financials 0.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LBRX
1
LB Pharmaceuticals
LBRX
$1.57B
$49.4M 7.85%
1,523,022
+203,660
+15% +$5.98M
NRIX icon
2
Nurix Therapeutics
NRIX
$2.8B
$38.2M 6.06%
1,573,220
-170,000
-10% -$2.9M
IMCR icon
3
Immunocore
IMCR
$1.93B
$33.8M 5.36%
1,063,234
+380,637
+56% +$11.3M
TRAX
4
First Tracks Biotherapeutics
TRAX
$1.61B
$30.5M 4.84%
+1,514,000
New +$28.3M
FDMT icon
5
4D Molecular Therapeutics
FDMT
$868M
$29.6M 4.7%
2,227,917
+925,000
+71% +$9.01M
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12.8B
$29.3M 4.65%
+512,000
New +$28M
DSGN icon
7
Design Therapeutics
DSGN
$981M
$29M 4.6%
2,001,282
+1,149,269
+135% +$14.3M
XENE icon
8
Xenon Pharmaceuticals
XENE
$5.85B
$26.6M 4.22%
440,000
– –
MIRM icon
9
Mirum Pharmaceuticals
MIRM
$5.98B
$26.1M 4.15%
223,312
-110,000
-33% -$11M
INSM icon
10
Insmed
INSM
$27.1B
$24.6M 3.9%
+230,331
New +$27.9M
CYTK icon
11
Cytokinetics
CYTK
$10.8B
$24.5M 3.9%
288,089
-11,911
-4% -$855K
SNDX icon
12
Syndax Pharmaceuticals
SNDX
$1.78B
$24.3M 3.85%
1,110,000
+408,179
+58% +$8.49M
NGNE icon
13
Neurogene
NGNE
$817M
$22.5M 3.57%
714,885
-67,902
-9% -$1.87M
KLRA
14
Kailera Therapeutics
KLRA
$2.3B
$21.7M 3.44%
+984,786
New +$21.6M
RVMD icon
15
Revolution Medicines
RVMD
$45.3B
$21.7M 3.44%
115,750
-129,250
-53% -$18.9M
IKT icon
16
Inhibikase Therapeutics
IKT
$349M
$18.4M 2.92%
9,051,318
+993,973
+12% +$1.78M
INCY icon
17
Incyte
INCY
$26.3B
$17.6M 2.79%
+155,000
New +$15.4M
AVTX icon
18
Avalo Therapeutics
AVTX
$1.06B
$16.5M 2.62%
+891,881
New +$14.1M
MLTX icon
19
MoonLake Immunotherapeutics
MLTX
$1.32B
$14.6M 2.32%
+750,000
New +$13.6M
FTH
20
Faeth Therapeutics
FTH
$892M
$12.9M 2.05%
515,335
+390,335
+312% +$9.03M
XFOR icon
21
X4 Pharmaceuticals
XFOR
$412M
$12M 1.91%
2,571,478
– –
IRD
22
Opus Genetics
IRD
$342M
$11.3M 1.79%
2,743,658
+2,243,658
+449% +$10.5M
SLGL icon
23
Sol-Gel Technologies
SLGL
$268M
$10.3M 1.64%
139,445
+53,949
+63% +$3.96M
AURA icon
24
Aura Biosciences
AURA
$811M
$10.2M 1.63%
+1,443,333
New +$10.3M
IPSC icon
25
Century Therapeutics
IPSC
$393M
$10.1M 1.61%
4,134,969
+1,684,976
+69% +$3.85M
1
2

Similar funds

SJIC
St. James Investment Company Southlake, Texas $630M AUM 12.48% 1-Year Est. Return
SFO
Stenger Family Office Naperville, Illinois $629M AUM 25.67% 1-Year Est. Return
PPC
Park Place Capital Homewood, Alabama $629M AUM 18.27% 1-Year Est. Return
ACGA
Atlanta Consulting Group Advisors Atlanta, Georgia $631M AUM 22.46% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
MC
Machina Capital Paris, France $631M AUM 11.37% 1-Year Est. Return
GPTE
Generali Powszechne Towarzystwo Emerytalne Warsaw, Poland $631M AUM 32.98% 1-Year Est. Return
KNW
Kesler Norman & Wride Ogden, Utah $631M AUM 27.63% 1-Year Est. Return

Trails Edge Capital Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Trails Edge Capital Partners held 40 positions worth $630M, up 44% from $437M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Trails Edge Capital Partners deployed $111M of net new capital in Q2 2026, opening 13 new positions and adding to 10 existing holdings. Its largest new stake was First Tracks Biotherapeutics: 1,514,000 shares worth $30.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Revolution Medicines, an estimated $18.9M trimmed.

  • Trails Edge Capital Partners's largest Q2 2026 buy was First Tracks Biotherapeutics: 1,514,000 shares worth $30.5M.
  • Trails Edge Capital Partners added most to Design Therapeutics in Q2 2026, an estimated $14.3M increase.
  • Trails Edge Capital Partners's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $18.9M.
  • Trails Edge Capital Partners fully exited Vaxcyte in Q2 2026, selling an estimated $38.5M.
  • Trails Edge Capital Partners's ten largest holdings make up 50% of its $630M portfolio in Q2 2026.
  • Trails Edge Capital Partners opened 13 new positions and closed 5 in Q2 2026.
  • Trails Edge Capital Partners's portfolio value rose 44% quarter-over-quarter to $630M.

Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.